# A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

> **NCT06575426** · PHASE1,PHASE2 · RECRUITING · sponsor: **Otsuka Pharmaceutical Factory, Inc.** · enrollment: 13 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1
- Hypoglycemia
- Islet Cell Transplantation
- Type 1 Diabetes
- Type 1 Diabetes Mellitus
- T1D
- T1DM
- T1DM - Type 1 Diabetes Mellitus
- Type 1 Diabetes (T1D)
- Severe Hypoglycemia
- Xenotransplantation
- Hypoglycemic Episode
- Islet Transplantation in Diabetes Mellitus Type 1
- Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Immune System Diseases
- Autoimmune Diseases
- Metabolic Disease

## Interventions

- **COMBINATION_PRODUCT:** OPF-310

## Key facts

- **NCT ID:** NCT06575426
- **Lead sponsor:** Otsuka Pharmaceutical Factory, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575426, "A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06575426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*